Diagnosis and treatment of pneumocystosis and toxoplasmosis in the immunosuppressed host.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002555:Cerebrospinal Fluid / Q000382:microbiology; D004338:Drug Combinations; D005455:Fluorescent Antibody Technique; D006386:Hemagglutination Tests; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D002955:Leucovorin / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy; D011020:Pneumonia, Pneumocystis / Q000175:diagnosis / Q000188:drug therapy; D011739:Pyrimethamine / Q000627:therapeutic use; D013411:Sulfadiazine / Q000627:therapeutic use; D014122:Toxoplasma / Q000302:isolation & purification; D014123:Toxoplasmosis / Q000175:diagnosis / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D007166:Immunosuppressive Agents; D013411:Sulfadiazine; D002955:Leucovorin; D011739:Pyrimethamine